CSFB Lowers Myogen to Neutral

Analyst Mark Augustine downgraded on disappointing trial results for the company's heart-failure drug

Credit Suisse First Boston downgraded Myogen (MYOG ) to neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.